Next Article in Journal
Senolytic Targeting of Bcl-2 Anti-Apoptotic Family Increases Cell Death in Irradiated Sarcoma Cells
Previous Article in Journal
Metabolic Effects of Recurrent Genetic Aberrations in Multiple Myeloma
Previous Article in Special Issue
Artificial Intelligence for Histology-Based Detection of Microsatellite Instability and Prediction of Response to Immunotherapy in Colorectal Cancer
Open AccessReview

COVID-19 and Its Impact on Upper Gastrointestinal (GI) Cancer Management

1
North Middlesex University Hospital, Sterling Way, London N181QX, UK
2
Department of GI Oncology, University College Hospital, 235 Euston Road, Bloomsbury, London NW1 2BU, UK
3
UCL Cancer Trials Centre 72 Huntley Street, Bloomsbury, London WC1E 6DD, UK
*
Author to whom correspondence should be addressed.
Academic Editor: Marta Lukaszewicz-Zajac
Cancers 2021, 13(3), 397; https://doi.org/10.3390/cancers13030397
Received: 31 December 2020 / Revised: 14 January 2021 / Accepted: 19 January 2021 / Published: 21 January 2021
In the midst of a pandemic resulting from the new virus, severe acute respiratory syndrome coronavirus 2, we carried out a review of the impact of the virus on patients suffering with upper gastrointestinal cancers. This previously unknown, but highly infectious virus, has rapidly spread throughout the world, causing devastation to people’s health on a global scale. The scientific and medical community have had to adapt and learn how to manage the virus, which has had knock on effects to patients suffering other diseases. Health services have been severely disrupted, so we reviewed the impact of this, specifically relating to the diagnosis and treatment of patients with upper gastrointestinal cancers. The situation is rapidly changing; therefore, we share the findings of our critical analysis of the available literature.
Coronavirus disease 2019 (COVID-19), caused by the novel, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, has left dramatic footprints on human health and economy. Cancer, whilst not an infective disease, is prevalent in epidemic proportions and cannot be pretermitted due to the impact of COVID-19. As we emanate from the second national lockdown in the UK with mixed feelings of hope and despair—due to vaccination and new COVID-19 variant, respectively—we reflect on the impact of the first wave on the provision on diagnosis and management of with upper gastrointestinal (UGI) cancers. This review provides a critical analysis of available literature on COVID-19 and its impact on cancer management in general and that of UGI cancers in particular. View Full-Text
Keywords: gastrointestinal; cancer; coronavirus; endosocopy; COVID-19; SARS-Cov-2 gastrointestinal; cancer; coronavirus; endosocopy; COVID-19; SARS-Cov-2
Show Figures

Figure 1

MDPI and ACS Style

Fernando, S.; Veli, M.; Mohammadi, B.; Millar, A.; Khan, K. COVID-19 and Its Impact on Upper Gastrointestinal (GI) Cancer Management. Cancers 2021, 13, 397. https://doi.org/10.3390/cancers13030397

AMA Style

Fernando S, Veli M, Mohammadi B, Millar A, Khan K. COVID-19 and Its Impact on Upper Gastrointestinal (GI) Cancer Management. Cancers. 2021; 13(3):397. https://doi.org/10.3390/cancers13030397

Chicago/Turabian Style

Fernando, Shalini; Veli, Mesel; Mohammadi, Borzoueh; Millar, Andrew; Khan, Khurum. 2021. "COVID-19 and Its Impact on Upper Gastrointestinal (GI) Cancer Management" Cancers 13, no. 3: 397. https://doi.org/10.3390/cancers13030397

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop